title: ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.
abstract: The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies. The ESMO-MCBS is intended to both assist oncologists in explaining the likely benefits of a particular treatment to their patients as well as to aid public health decision makers' prioritise therapies for reimbursement. From its inception the ESMO-MCBS Working Group has invited questions and critiques to promote understanding and to address misunderstandings regarding the nuanced use of the scale, and to identify shortcomings in the scale to be addressed in future planned revisions and updates. The ESMO-MCBS V.1.0 has attracted many questions regarding its development, structure and potential applications. These questions, together with responses from the ESMO-MCBS Working Group, have been edited and collated, and are herein presented as a supplementary resource.
authors.affiliation: Cancer Pain and Palliative Medicine Service, Department of Medical Oncology , Shaare Zedek Medical Center , Jerusalem , Israel.
authors.forename: N I
authors.initials: NI
authors.lastname: Cherny
authors.affiliation: Kings Health Partners Integrated Cancer Centre, Kings College London, Institute of Cancer Policy , London , UK.
authors.forename: R
authors.initials: R
authors.lastname: Sullivan
authors.affiliation: University of Athens and Frontiers of Science Foundation-Hellas , Athens , Greece.
authors.forename: U
authors.initials: U
authors.lastname: Dafni
authors.affiliation: Department of Medical Oncology , Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute , Amsterdam , The Netherlands.
authors.forename: J M
authors.initials: JM
authors.lastname: Kerst
authors.affiliation: Department of Medical Oncology , IRCCS San Martino IST , Genova , Italy.
authors.forename: A
authors.initials: A
authors.lastname: Sobrero
authors.affiliation: Division of Oncology , Medical University Vienna , Vienna , Austria.
authors.forename: C
authors.initials: C
authors.lastname: Zielinski
authors.affiliation: Jules Bordet Institute, Université Libre de Bruxelles , Brussels , Belgium.
authors.forename: M J
authors.initials: MJ
authors.lastname: Piccart
authors.affiliation: EORTC HQ , Brussels , Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Bogaerts
authors.affiliation: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology , Barcelona , Spain.
authors.forename: J
authors.initials: J
authors.lastname: Tabernero
authors.affiliation: European Society for Medical Oncology , Viganello-Lugano , Switzerland.
authors.forename: N J
authors.initials: NJ
authors.lastname: Latino
authors.affiliation: Department of Medical Oncology , University Medical Center Groningen, University of Groningen , Groningen , The Netherlands.
authors.forename: E G E
authors.initials: EG
authors.lastname: de Vries
keywords: ESMO; Health technology assessment; MCBS; Methodically validity